Novo Nordisk‘s Stock Performance and Market Position

Novo Nordisk, once Europe’s⁢ most⁢ valuable company surpassing⁣ luxury giant LVMH in 2022, has experienced⁣ a meaningful downturn. The company’s share price retreated 10% in 2024 and⁤ has fallen by more than 40% in 2025 as⁢ of august 30, 2024. This decline follows a period of stock accumulation at ⁣the ⁣end of 2024.

Investor concerns center around increasing competition, particularly from US pharmaceutical company Eli Lilly, slowing market growth, and uncertainties surrounding the ⁤growth⁤ of new generation treatments.

Rising Competition in the Weight Loss drug Market

‍ Competition in the weight loss medication market is ⁢intensifying,threatening‍ Novo Nordisk’s market share. Eli lilly ‍is ⁤emerging as a key competitor, poised ⁢to challenge Novo Nordisk’s dominance.
⁣

Impact of US Policies and Tariffs

President Trump’s calls for cheaper ‍medications and the potential for US tariffs have created headwinds⁤ for⁢ the European pharmaceutical⁣ sector,⁤ including ⁤Novo Nordisk.⁣ While the recent US-EU agreement offers some⁤ reassurance, the threat of future policy changes remains.
⁤⁤

⁤ ⁣ The US ⁣Food and Drug Administration (FDA) authorized American pharmacists to compound ⁣versions of novo Nordisk’s medications in response ‍to product scarcity. Novo Nordisk has stated it is evaluating legal action against companies that ⁣fail to meet the deadline to halt ⁢the manufacture of compounded drugs. Reuters ⁤reported on this development ⁤on ⁤March 15, 2024.

Decline in Pharmaceutical Exports

⁤ Pharmaceutical exports are projected ⁢to decline ‍significantly. after growing by over 8% in 2024, external sales of pharmaceutical ⁤products are expected to sink to 1% this ‍year. The ⁣overall growth of total goods exports is also forecast to retreat from 10% in 2024⁤ to 3% in 2025.